Back to Business

Cabaletta Bio reports phase 1/2 data for autoimmune therapy

Business November 8, 2026 at 3:04 PM

Cabaletta Bio reports phase 1/2 data for autoimmune therapy

Investing.com

Read the full story at Investing.com

More Stories

The Real Estate Selloff: High Yield From High Rates

The Real Estate Selloff: High Yield From High Rates

🇺🇸 Seeking Alpha 38m ago

Paul Gama, P&G CEO-health care, sells $477,510 in stock

Paul Gama, P&G CEO-health care, sells $477,510 in stock

🇺🇸 Investing.com 52m ago

As AI trade tires, BCA calls for European stocks to beat Wall Street

As AI trade tires, BCA calls for European stocks to beat Wall Street

🇺🇸 Investing.com 52m ago

Your world briefing, in your pocket

Curated news from 12 countries and 10 languages. Coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play